2-(3-甲氧基苯基)喹啉-4-羧酸 | 159782-19-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2-(3-甲氧基苯基)喹啉-4-羧酸
• 英文名称: 2-(3-methoxyphenyl)quinoline-4-carboxylic acid
• 英文别名: 2-(3-methoxyphenyl)-4-quinolinecarboxylic acid
• CAS: 159782-19-1
• 化学式: C₁₇H₁₃NO₃
• mdl: MFCD00578118
• 分子量: 279.295
• InChiKey: YBOFRTWITLNSGS-UHFFFAOYSA-N

物化性质

• 熔点：
  223.8-225.6 °C(Solv: ethanol (64-17-5))
• 沸点：
  479.7±40.0 °C(Predicted)
• 密度：
  1.277±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  2-(3-甲氧基苯基)喹啉-4-羧酸 在 氯化亚砜 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 生成 N-(3-fluoro-4-(6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinolin-4-yloxy)phenyl)-2-(3-methoxyphenyl)quinoline-4-carboxamide
  参考文献：
  名称：

  Design, synthesis and antitumour activity of bisquinoline derivatives connected by 4-oxy-3-fluoroaniline moiety

  摘要：

  A series of novel bisquinoline derivatives connected by a 4-oxy-3-fluoroaniline moiety were synthesized and evaluated for their in vitro antitumour activities against a panel of five cancer cell lines (H460, HT-29, MKN-45, U87MG, and SMMC-7721). Most of compounds tested showed a potent activity and high selectivity towards the H460 and MKN-45 cell lines. Among the compounds tested, six (15d, 15e, 15m, 15n, 16a, and 16i) were further examined for their c-Met kinase activity; the compounds showed high efficacy with IC50 values in the single-digit nM range. An analysis of structure activity relationships indicated that an unsubstituted or a halogen-substituted phenyl ring on the 2-arylquinoline-4-carboxamide moiety was favourable for antitumour activity. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.04.001
• 作为产物：
  描述：

  2-羟基亚氨基-n-苯乙酰胺 在 硫酸 、 potassium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 生成 2-(3-甲氧基苯基)喹啉-4-羧酸
  参考文献：
  名称：

  Design, synthesis and antitumour activity of bisquinoline derivatives connected by 4-oxy-3-fluoroaniline moiety

  摘要：

  A series of novel bisquinoline derivatives connected by a 4-oxy-3-fluoroaniline moiety were synthesized and evaluated for their in vitro antitumour activities against a panel of five cancer cell lines (H460, HT-29, MKN-45, U87MG, and SMMC-7721). Most of compounds tested showed a potent activity and high selectivity towards the H460 and MKN-45 cell lines. Among the compounds tested, six (15d, 15e, 15m, 15n, 16a, and 16i) were further examined for their c-Met kinase activity; the compounds showed high efficacy with IC50 values in the single-digit nM range. An analysis of structure activity relationships indicated that an unsubstituted or a halogen-substituted phenyl ring on the 2-arylquinoline-4-carboxamide moiety was favourable for antitumour activity. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.04.001

文献信息

• [EN] GLUCOSE TRANSPORT INHIBITORS<br/>[FR] INHIBITEURS DE TRANSPORT DU GLUCOSE
  申请人：BAYER PHARMA AG

  公开号：WO2016202898A1

  公开（公告）日：2016-12-22

  The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

  本发明涉及选择性抑制葡萄糖转运蛋白1（GLUT1）的化合物，涉及制备该类化合物的方法，涉及包含该类化合物的药物组合物和药物组合物，涉及利用该类化合物制造用于治疗或预防疾病的药物组合物，以及用于制备该类化合物的中间化合物。
• [EN] NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087<br/>[FR] NOUVEAUX INHIBITEURS DE L'ACÉTYL COENZYME A CARBOXYLASE (ACC) ET UTILISATIONS DANS LE TRAITEMENT DE L'OBÉSITÉ ET DU DIABÈTE SUCRÉ - 087
  申请人：ASTRAZENECA AB

  公开号：WO2009082346A1

  公开（公告）日：2009-07-02

  The present invention relates to Acetyl Coenzyme A Carboxylase (ACC) inhibitors according to formula (I), or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, E, L, Z and n are as defined herein, to processes for preparing such compounds, to pharmaceutical compositions containing them, to the use of such inhibitors and to methods for th eir therapeutic use, particularly in the treatments of obesity and diabetes mellitus.

  本发明涉及根据式（I）的乙酰辅酶A羧化酶（ACC）抑制剂，或其对映体，或其药用可接受的盐，其中R1、R2、R3、R4、R5、E、L、Z和n的定义如本文所述，以及制备此类化合物的方法，含有它们的药物组合物，使用这种抑制剂以及用于它们的治疗用途的方法，特别是用于肥胖和糖尿病的治疗。
• Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models
  作者：Ken Yamada、Julian Levell、Taeyong Yoon、Darcy Kohls、David Yowe、Dean F. Rigel、Hidetomo Imase、Jun Yuan、Kayo Yasoshima、Keith DiPetrillo、Lauren Monovich、Lingfei Xu、Meicheng Zhu、Mitsunori Kato、Monish Jain、Neeraja Idamakanti、Paul Taslimi、Toshio Kawanami、Upendra A. Argikar、Vidya Kunjathoor、Xiaoling Xie、Yukiko I. Yagi、Yuki Iwaki、Zachary Robinson、Hyi-Man Park

  DOI：10.1021/acs.jmedchem.7b00708

  日期：2017.8.24

  The observed structure–activity relationship of three distinct ATP noncompetitive With-No-Lysine (WNK) kinase inhibitor series, together with a crystal structure of a previously disclosed allosteric inhibitor bound to WNK1, led to an overlay hypothesis defining core and side-chain relationships across the different series. This in turn enabled an efficient optimization through scaffold morphing, resulting

  观察到的三种不同的ATP非竞争性无赖氨酸（WNK）激酶抑制剂系列的结构活性关系，以及先前公开的与WNK1结合的变构抑制剂的晶体结构，导致定义核心和侧链关系的重叠假说跨越不同的系列。反过来，这可以通过支架变形实现有效的优化，从而得到具有适合体内应用的选择性，细胞效价和药代动力学特性的良好平衡的化合物概念验证研究。口服时，优化的化合物可降低过表达人WNK1的小鼠的血压，并在自发性高血压大鼠（SHR）中诱导利尿，利尿和利尿，这证实了这种抑制WNK激酶活性的机制可有效调节心血管稳态。
• New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087
  申请人：Blomberg David

  公开号：US20090306133A1

  公开（公告）日：2009-12-10

  The present invention relates to Acetyl Coenzyme A Carboxylase (ACC) inhibitors according to formula (I), or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , R 4 , R 5 , E, L, Z and n are as defined herein, to processes for preparing such compounds, to pharmaceutical compositions containing them, to the use of such inhibitors and to methods for their therapeutic use, particularly in the treatments of obesity and diabetes mellitus.

  本发明涉及Acetyl辅酶A羧化酶（ACC）抑制剂，其按照公式（I）或其对映体或其药学上可接受的盐，其中R1，R2，R3，R4，R5，E，L，Z和n的定义如本文所述，以及制备这种化合物的过程，包含它们的制药组合物，使用这种抑制剂的用途以及它们的治疗用途的方法，特别是在肥胖和糖尿病治疗中的应用。
• Exploration of Isoxazole‐Carboxylic Acid Methyl Ester Based 2‐Substituted Quinoline Derivatives as Promising Antitubercular Agents
  作者：Santosh Kumar Sahoo、Mohammad Naiyaz Ahmad、Grace Kaul、Srinivas Nanduri、Arunava Dasgupta、Sidharth Chopra、Venkata Madhavi Yaddanapudi

  DOI：10.1002/cbdv.202200324

  日期：2022.7

  pursuit of potent anti-TB agents active against drug resistant tuberculosis (DR-TB), herein we report synthesis and bio-evaluation of a new series of isoxazole-carboxylic acid methyl ester based 2-substituted quinoline derivatives. Preliminary evaluation indicated selectivity towards Mtb H37Rv, with no inhibition of non-tubercular mycobacterial (NTM) & bacterial pathogen panel. Out of 36 synthesized compounds

  为了追求对耐药结核病 (DR-TB) 有活性的有效抗结核药物，我们在此报告了一系列基于异恶唑-羧酸甲酯的 2-取代喹啉衍生物的合成和生物评价。初步评估表明对 Mtb H37Rv 具有选择性，对非结核分枝杆菌 (NTM) 和细菌病原体组没有抑制作用。在 36 种合成化合物中，大多数化合物对 Mtb H37Rv 具有显着抑制作用（MIC 0.5-8 μg/mL）。针对 Vero 细胞的细胞活力测试显示没有显着的细胞毒性。此外，针对耐药菌株 (DR-Mtb) 的筛选发现命中化合物显示出有希望的效力 (MIC 1-4 μg/mL)。命中的结构优化导致了先导化合物的鉴定，证明了对药物敏感的 Mtb (MIC 0. 12 μg/mL) 和耐药 Mtb (MIC 0.25-0.5 μg/mL) 以及高选择性指数 (SI) >80。总之，具有可观的选择性和有效的活性，这些化学型显示出有望成为潜在的抗结核病候选者。